drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (biologic)
drug_description
Autologous cellular immunotherapy comprising dendritic cells and activated effector T cells; dendritic cells present tumor antigens via MHC I/II to prime tumor-specific T cells, and infused T cells mediate cytotoxicity via perforin/granzyme and IFN-γ.
nci_thesaurus_concept_id
C131336
nci_thesaurus_definition
A dendritic cell (DC) vaccine in which autologous DCs are loaded with multiple tumor-associated antigens (TAAs), with potential immunostimulating and antineoplastic activities. Upon re-infusion into the patient, the antigen-pulsed DCs stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the TAA-expressing tumor cells.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
DC VACCINE
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous dendritic cells loaded with tumor antigens present peptides via MHC I/II to prime and expand tumor-specific T cells, while co-infused activated effector T cells mediate tumor cell killing through perforin/granzyme release and IFN-γ–driven Th1 cytotoxic responses.
drug_name
MASCT-I
nct_id_drug_ref
NCT06277154